Ovarian cancer · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | ~16.4 mo | ~30.0 mo | ~24 | ~R 120 737 PFS proxy · indirect | 32 |
Carboplatin monotherapy Variant #01 | — | R 1 231 | 21d | — | — | — | — | 2 |
Observation Partial | — | — | — | ~20.4 mo | ~38.6 mo | — | — | 2 |
3 of 3 regimens shown